211 related articles for article (PubMed ID: 35149591)
1. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
Bazan-Peregrino M; Garcia-Carbonero R; Laquente B; Álvarez R; Mato-Berciano A; Gimenez-Alejandre M; Morgado S; Rodríguez-García A; Maliandi MV; Riesco MC; Moreno R; Ginestà MM; Perez-Carreras M; Gornals JB; Prados S; Perea S; Capella G; Alemany R; Salazar R; Blasi E; Blasco C; Cascallo M; Hidalgo M
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 35149591
[TBL] [Abstract][Full Text] [Related]
2. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
Garcia-Carbonero R; Bazan-Peregrino M; Gil-Martín M; Álvarez R; Macarulla T; Riesco-Martinez MC; Verdaguer H; Guillén-Ponce C; Farrera-Sal M; Moreno R; Mato-Berciano A; Maliandi MV; Torres-Manjon S; Costa M; Del Pozo N; Martínez de Villarreal J; Real FX; Vidal N; Capella G; Alemany R; Blasi E; Blasco C; Cascalló M; Salazar R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338084
[TBL] [Abstract][Full Text] [Related]
3. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R
Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696
[TBL] [Abstract][Full Text] [Related]
5. Advances in oncolytic adenovirus therapy for pancreatic cancer.
Nattress CB; Halldén G
Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
[TBL] [Abstract][Full Text] [Related]
6. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
[TBL] [Abstract][Full Text] [Related]
8. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
[No Abstract] [Full Text] [Related]
9. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11.
Mato-Berciano A; Morgado S; Maliandi MV; Farrera-Sal M; Gimenez-Alejandre M; Ginestà MM; Moreno R; Torres-Manjon S; Moreno P; Arias-Badia M; Rojas LA; Capellà G; Alemany R; Cascallo M; Bazan-Peregrino M
J Control Release; 2021 Apr; 332():517-528. PubMed ID: 33675877
[TBL] [Abstract][Full Text] [Related]
10. A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
Weber HL; Gidekel M; Werbajh S; Salvatierra E; Rotondaro C; Sganga L; Haab GA; Curiel DT; Cafferata EG; Podhajcer OL
Clin Cancer Res; 2015 Apr; 21(7):1665-74. PubMed ID: 25573380
[TBL] [Abstract][Full Text] [Related]
11. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.
Gayral M; Lulka H; Hanoun N; Biollay C; Sèlves J; Vignolle-Vidoni A; Berthommé H; Trempat P; Epstein AL; Buscail L; Béjot JL; Cordelier P
Hum Gene Ther; 2015 Feb; 26(2):104-13. PubMed ID: 25423447
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.
Bots STF; Harryvan TJ; Groeneveldt C; Kinderman P; Kemp V; van Montfoort N; Hoeben RC
Mol Oncol; 2024 May; 18(5):1245-1258. PubMed ID: 38037840
[TBL] [Abstract][Full Text] [Related]
13. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
Li D; Schaub N; Guerin TM; Bapiro TE; Richards FM; Chen V; Talsania K; Kumar P; Gilbert DJ; Schlomer JJ; Kim SJ; Sorber R; Teper Y; Bautista W; Palena C; Ock CY; Jodrell DI; Pate N; Mehta M; Zhao Y; Kozlov S; Rudloff U
Mol Cancer Ther; 2021 Oct; 20(10):1926-1940. PubMed ID: 34376576
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.
Jung KH; Choi IK; Lee HS; Yan HH; Son MK; Ahn HM; Hong J; Yun CO; Hong SS
Cancer Lett; 2017 Jun; 396():155-166. PubMed ID: 28315430
[TBL] [Abstract][Full Text] [Related]
15. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
16. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.
Kurosaki H; Nakatake M; Sakamoto T; Kuwano N; Yamane M; Ishii K; Fujiwara Y; Nakamura T
Cells; 2021 Apr; 10(5):. PubMed ID: 33922406
[TBL] [Abstract][Full Text] [Related]
17. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
18. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M
Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556
[TBL] [Abstract][Full Text] [Related]
19. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.
Martínez-Vélez N; Xipell E; Vera B; Acanda de la Rocha A; Zalacain M; Marrodán L; Gonzalez-Huarriz M; Toledo G; Cascallo M; Alemany R; Patiño A; Alonso MM
Clin Cancer Res; 2016 May; 22(9):2217-25. PubMed ID: 26603261
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]